First-Line Alternatives to Metformin for Type 2 Diabetes

Primary Alternative: SGLT2 Inhibitors

The American College of Physicians and the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend SGLT2 inhibitors as the preferred first-line alternative to metformin for patients with type 2 diabetes, due to their proven cardiovascular and renal protection independent of metformin use, with a Grade 1A recommendation for patients with eGFR ≥30 mL/min/1.73 m² 1, 2
SGLT2 inhibitors reduce the risk of cardiovascular death or heart failure hospitalization by 31%, and major adverse cardiovascular events by 20%, with benefits consistent across the full spectrum of cardiovascular risk 4
The European Society of Cardiology (ESC) guidelines support the use of SGLT2 inhibitors in patients with established cardiovascular disease or high/very high cardiovascular risk, with a Class IA recommendation 5

The KDIGO guidelines recommend long-acting GLP-1 receptor agonists as the second choice, with a Grade 1B recommendation, when SGLT2 inhibitors cannot be used 1, 2
GLP-1 receptor agonists, such as liraglutide and semaglutide, reduce new or worsening nephropathy by 22-36%, and demonstrate cardiovascular mortality reduction, with particularly strong benefits in patients with eGFR <60 mL/min/1.73 m² 3
The American Diabetes Association (ADA) supports the use of GLP-1 receptor agonists in patients with type 2 diabetes, due to their glucose-lowering effect, weight loss, and cardiovascular benefits 3

The ESC guidelines recommend that patients with established cardiovascular disease or high/very high cardiovascular risk should receive SGLT2 inhibitors or GLP-1 receptor agonists as first-line therapy, with metformin added if HbA1c targets are not met, with a Class IA recommendation 5
The KDIGO guidelines recommend evaluating HbA1c after approximately 3 months and proceeding to combination therapy if targets are not achieved, with a Grade 1A recommendation 6